

Gleamer

Category:

Best Startup

Company Name:

Gleamer

Turnover and/or Funding:

Gleamer has raised \$44 million in funding and generated over €20 million in annual recurring revenue (ARR), with more than €35 million ARR in signed contracts.

Sub-Category:

Medical Technology / Digital Health

Corporate history (creation, key milestones, main funding,...)Information on Condition / Disease and need for solution / product (prevalence, existing treatments / solutions):

Founded in 2017, Gleamer is an Artificial Intelligence company at the forefront of revolutionizing medical imaging. Our vision is to develop a comprehensive AI copilot that paves the way for precision medicine, with a deep commitment to making optimal care accessible to all.

Our Mission and Team

Gleamer's mission is to create AI solutions that match expert performance while ensuring ease of integration and a seamless user experience. This is achieved through the collaborative efforts of our multidisciplinary team, which includes AI specialists and radiologist experts. Our solutions are designed to be intuitive and user-friendly, making advanced AI accessible to medical professionals.

Proven Track Record

- Clinical Studies and Publications: With over 80 clinical studies and numerous significant publications, Gleamer has demonstrated its commitment to scientific excellence.
- Global Reach: Our AI solutions have been integrated into more than 2,500 institutions worldwide, enhancing the care of over a million patients every month.

- Awards and Recognition: We have received the prestigious Alexander Margulis Award for the best Radiology paper in 2022 and the EuroMinnies award for best vendor in radiology in 2023.
- Financial Success: We have raised 44 million USD in funding and generated over 20 million EUR in annual recurring revenue (ARR), with more than 35 million EUR (ARR) in signed contracts.

Addressing Key Healthcare Challenges

Since our inception, we have viewed AI as a crucial solution to address the rising demand for medical imaging, driven by an aging population, the increasing prevalence of chronic diseases, and challenges in access to care. Our AI copilot assists radiologists by improving diagnostic accuracy, enabling early diagnosis, speeding up treatment, and optimizing productivity, all of which contribute to reducing healthcare costs and addressing the shortage of medical professionals.

Global Impact and Future Vision

Gleamer's solutions are currently deployed in over 2,500 hospitals and imaging centers across 45 countries. Our innovations are developed in close collaboration with medical experts, data scientists, AI specialists, healthcare providers, and many partners. This commitment to collaboration ensures that each of our solutions is rigorously tested and validated, contributing to the global e-health ecosystem, particularly in medical imaging.

Commitment to Excellence

Our dedication to developing high-performance AI solutions is reflected in our significant scientific contributions, with 35 publications in prestigious peer-reviewed journals. These contributions highlight our commitment to advancing medical knowledge and improving patient care globally.

Gleamer is proud to be a leader in the field of medical imaging AI, continuously striving to enhance healthcare outcomes through innovative technology and collaborative partnerships.

History of the development of the solution/product (Intellectual Property, preclinical and clinical datas, development collaborations):

Founded in 2017, Gleamer's mission is to equip radiologists with an expert-level, modality-agnostic AI copilot. Our cloud-native Gleamer Copilot® platform delivers FDA-cleared imaging applications through a single PACS-integrated interface providing explainable ROI visualisations.

Data-driven design. From 2018-2021 we aggregated millions of anonymised radiographs from hundreds of institutions under GDPR & HIPAA-compliant agreements.

BoneView US: fracture CAdE/CADx

Trained on 500k+ skeletal images, BoneView obtained CE-mark in 2020 and FDA clearance K212365 (Mar 2022). In a U.S. multi-reader study of 600 exams, AI assistance raised sensitivity 10.4 %, cut false-negatives 29 % and shortened reading by 6 s; standalone AUC = 0.97 gleamer.ai. A 2023 label expansion made BoneView the first AI cleared for paediatric fracture detection.

BoneMetrics US: automated Cobb angle.

Trained on 5000 + annotated radiographs from more than 20 public and private settings from multiple patient populations and geographies.. Multi-centre validation (345 U.S. patients) showed mean-absolute-error 2.6° overall and 1.9° in children SpringerLink. FDA 510(k) K241593 (5 Feb 2025) authorises use in patients ≥ 4 y, the first fully automated scoliosis-measurement tool in the U.S.FDA Access Data.

ChestView US: multi-finding chest CAdE.

Built on large database of 100k+ images, ChestView detects 4 critical findings (lung nodules, pleural space abnormality, pneumothorax and consolidation) with pixel-level explainability. It secured FDA clearance on 25 Mar 2025, the first multi-finding CAdE for digital radiography, and showed significant reader-sensitivity gains in the pivotal study gleamer.ai.

Collaborative development:

Key partners include Boston University School of Medicine collaborated with Gleamer on our BoneView validation study gleamer.ai, UCLA Health, Einstein Medical Center, St. Luke's Health System, Henry Ford Health and Baptist Health are all using our AI applications to inform their clinical practice. Deployment alliances with Bayer Calantic, Fujifilm Synapse, Aidoc and Blackford ensure seamless U.S. roll-out.

Clinical impact in the U.S. Since 2022, BoneView alone analyses >3 million exams/year and, together with the 2025 clearances, positions Copilot in >200 U.S. hospitals, contributing to the 2,500-institution global install base processing 35 million studies annually.

IP & quality framework. All code is developed under IEC 62304 processes, penetration-tested to SOC-2, and monitored through an ISO 27001 ISMS.

A reproducible pathway, robust data, peer-reviewed validation, FDA authorisations and industrial integrations, has delivered three best-in-class products on a unified platform that measurably improve accuracy and efficiency across U.S. X-ray practice today, while laying the IP, data and regulatory foundation for upcoming CT, MRI and

mammography modules.

Why this drug or device is innovative, the broad implications for future research, and/or how it will improve the human condition:

Gleamer Copilot®: A Modality-Agnostic AI Partner for Every Radiologist

Radiology sits at the nexus of every modern care pathway, yet worldwide demand for imaging is growing five times faster than the radiologist workforce.¹ Missed findings, delayed reports and diagnostic inequality are inevitable without new technology. Gleamer Copilot® addresses this crisis by shifting the paradigm from single-use algorithms to a unified, cloud-native copilot that delivers expert-level AI applications through one PACS-integrated interface.

Platform-level innovation, not point solutions

Most AI tools are siloed executables: one algorithm, one indication. Gleamer's Copilot is architected to dynamically load any of its FDA-cleared Gleamer applications (today BoneView®, ChestView and BoneMetrics) and presents results in a consistent, zero-click result inside the radiologist's existing viewer. A single installation therefore unlocks multiple clinical gains, accelerates future roll-outs and simplifies hospital cybersecurity and procurement.

BoneView US is a software-only CAdE/CADx that automatically highlights fractures in adults and children (>2.y.o) and returns the results as DICOM files to the PACS viewer. In a multicentre, 600-case reader study published in Radiology, AI assistance lifted mean reader sensitivity from 79 % to 87.7 % (+8.7 %, P = .003), increased specificity 4.1 %, cut false-positive marks 42 % and reduced reporting time 15 %; the stand-alone algorithm achieved an AUC of 0.94, outperforming all unaided readers.

BoneMetrics US automates Cobb-angle measurement on frontal spine radiographs and was cleared by the FDA on 5 February 2025 (K241593) for patients aged ≥ 4 years. In an independent, three-centre validation of 345 U.S. patients (179 paediatric, 166 adult), the algorithm's mean absolute error for the major curve was 2.6° (95 % CI 2.0-3.3) overall and 1.9° for children-well below the pre-specified 6° clinical threshold-demonstrating reproducibility comparable to expert consensus.

ChestView US analyses frontal and lateral chest radiographs for four critical findings-nodule, consolidation, pleural-space and mediastinum/hila abnormalities-and sends concurrent-reading heat-map overlays back to the radiologist. A 2023 500-case study showed that adjunctive use raised general-radiologist pneumothorax-detection sensitivity by 38.6 % and improved detection of pleural effusion (+8.5 %) and consolidation (+14.1 %) without prolonging interpretation time, confirming real-world value in emergency imaging

Together, the suite processes more than three million U.S. exams per year, raising reader sensitivity 8-14 %, cutting false negatives by up to one-third and shaving precious minutes off reporting time - metrics already translating into earlier treatment, fewer follow-up studies and lower costs.

Improving the human condition

By compressing expert knowledge into an always-available, workflow-native assistant, Gleamer Copilot levels the playing field between urban academic centres and under-resourced community hospitals, where a single radiologist may interpret thousands of studies alone. Faster, more accurate diagnoses mean fewer missed fractures in elderly patients, timelier recognition of pneumothorax in trauma bays, and objective scoliosis monitoring that spares children unnecessary radiation. As the Gleamer Copilot expands in the US to CT, MRI and mammography, its impact scales further with every modality - bringing high-quality imaging interpretation to anyone, anywhere.

Please provide appropriate references (PubMed, Abstract, Website):

- Duron, Loïc, et al. "Assessment of an AI Aid in Detection of Adult Appendicular Skeletal Fractures by Emergency Physicians and Radiologists: A Multicenter Cross-sectional Diagnostic Study." *Radiology*, vol. 300, no. 1, 2021, pp. 120-29. DOI: 10.1148/radiol.2021203886. PubMed
- United States, Food and Drug Administration. BoneView US (K212365) 510(k) Summary. 22 Mar. 2022, www.accessdata.fda.gov/cdrh_docs/pdf21/K212365.pdf. Accessed 14 July 2025. FDA Access Data
- BoneView 1.1-US (K222176) 510(k) Summary. 24 Mar. 2023, www.accessdata.fda.gov/cdrh_docs/pdf22/K222176.pdf. Accessed 14 July 2025. FDA Access Data
- BoneMetrics US (K241593) 510(k) Summary. 5 Feb. 2025, www.accessdata.fda.gov/cdrh_docs/pdf24/K241593.pdf. Accessed 14 July 2025. FDA Access Data
- Hayashi, Daichi, et al. "Deep Learning Algorithm Enables Automated Cobb Angle Measurements with High Accuracy." *Skeletal Radiology*, vol. 54, no. 7, 2025, pp. 1469-78. SpringerLink, DOI: 10.1007/s00256-024-04853-7. PubMed
- United States, Food and Drug Administration. ChestView US (K241620) 510(k) Summary. 25 Mar. 2025, www.accessdata.fda.gov/cdrh_docs/pdf24/K241620.pdf. Accessed 14 July 2025. FDA Access Data
- Bennani, Souhail, et al. "Using AI to Improve Radiologist Performance in Detection of Abnormalities on Chest Radiographs." *Radiology*, vol. 309, no. 3, 2023, e230860. DOI: 10.1148/radiol.230860. PubMed
- Hall, Jeff. "FDA Clears Gleamer's ChestView AI Software for CXR." *Diagnostic*

Imaging, 25 Mar. 2025,

www.diagnosticimaging.com/view/fda-clears-gleamer-chestview-ai-software-for-cxr.

Accessed 14 July 2025. Diagnostic Imaging

- "\"Study: AI Enhances Abnormality Detection on CXR Across Radiologist Experience Levels.\" Diagnostic Imaging, 13 Dec. 2023, www.diagnosticimaging.com/view/ai-abnormality-detection-cxr-across-radiologist-experience-levels. Accessed 14 July 2025. Diagnostic Imaging
- Gleamer. "\"GLEAMER Publishes in the Prestigious Journal (Radiology) the Compelling Results of a Clinical Study.\" Gleamer Insights, 19 July 2021, www.gleamer.ai/insights/radiology2021. Accessed 14 July 2025. gleamer.ai
- "\"Deep Learning Algorithm Enables Automated Cobb Angle Measurements with High Accuracy.\" Gleamer Evidence, 17 Dec. 2024, www.gleamer.ai/evidence/deep-learning-algorithm-enables-automated-cobb-angle-measurements-with-high-accuracy. Accessed 14 July 2025. gleamer.ai
- Regnard, Nor-Eddine, et al. "\"Artificial Intelligence-Assisted Detection of Fractures on Radiographs with BoneView: A Systematic Review.\" ResearchGate, Apr. 2025, www.researchgate.net/publication/392538359. Accessed 14 July 2025. researchgate.net

References File Document upload:

N/A